Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
Authors Greenberg J, Palmer JB, Chan WW, Correia CE, Whalley D, Shannon P, Sawicki GS
Received 10 December 2015
Accepted for publication 3 June 2016
Published 26 October 2016 Volume 2016:10 Pages 2163—2169
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Johnny Chen
Jonathan Greenberg,1 Jacqueline B Palmer,2 Wing W Chan,2 Catherine E Correia,1 Diane Whalley,3 Paul Shannon,3 Gregory S Sawicki1
1Division of Respiratory Diseases, Boston Children’s Hospital, Boston, MA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3RTI Health Solutions, Manchester, UK
Background: This study assessed treatment satisfaction of cystic fibrosis (CF) patients in a routine clinical setting for tobramycin inhalation powder (TIP), the first dry powder–inhaled antibiotic for Pseudomonas aeruginosa infection.
Methods: CF patients aged 6 years or older treated with at least one cycle of TIP completed a web survey on experience with TIP, including the Treatment Satisfaction Questionnaire for Medication (TSQM). Regression analysis determined the factors associated with TSQM global satisfaction.
Results: Eighty patients (mean age ± standard deviation: 24.4±9.4 years; 57.5% female; mean forced expiratory volume in 1 second ± standard deviation: 67.1%±27.3% predicted) completed the survey. The majority expressed satisfaction with TIP’s administration time (100%), time to clean (97.1%), portability (97.1%), and ease of use (94.3%). Effectiveness was significantly associated with TSQM global satisfaction (regression R-squared: 0.54).
Conclusion: Patient preferences for TIP were based on administration time and ease of use. Global satisfaction was related to greater patient-perceived effectiveness.
Keywords: cystic fibrosis, patient satisfaction, tobramycin, dry powder inhalers
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]